Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 57Carcinoma, Non-Small-Cell Lung 46Ovarian Neoplasms 31Stomach Neoplasms 22Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Lung Neoplasms 18Neoplasm Metastasis 17Fallopian Tube Neoplasms 14Triple Negative Breast Neoplasms 13Esophageal Neoplasms 13Esophageal Squamous Cell Carcinoma 10Colorectal Neoplasms 9Carcinoma, Ovarian Epithelial 9Melanoma 8Head and Neck Neoplasms 8Endometrial Neoplasms 8Uterine Cervical Neoplasms 6Pancreatic Neoplasms 6Carcinoma, Renal Cell 6Adenocarcinoma of Lung 6Urinary Bladder Neoplasms 5Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Advanced Solid Tumors 5Testicular Neoplasms 4Testicular Germ Cell Tumor 4Recurrence 4Carcinoma, Transitional Cell 4

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1durvalumab 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Cancer × Paclitaxel × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡